Choline magnesium trisalicylate

Identification

Name
Choline magnesium trisalicylate
Accession Number
DB01401
Type
Small Molecule
Groups
Approved
Description

Choline magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28% [1, 2].

Structure
Thumb
Synonyms
Not Available
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Choline Magnesium TrisalicylateCholine magnesium trisalicylate (500 mg/5mL)LiquidOralLannett Company, Inc.1997-02-05Not applicableUs
International/Other Brands
Tricosal / Trilisate
Categories
UNII
DJJ95FJP1H
CAS number
64425-90-7
Weight
Average: 539.814
Monoisotopic: 539.164188051
Chemical Formula
C26H29MgNO10
InChI Key
FQCQGOZEWWPOKI-UHFFFAOYSA-K
InChI
InChI=1S/3C7H6O3.C5H14NO.Mg/c3*8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7;/h3*1-4,8H,(H,9,10);7H,4-5H2,1-3H3;/q;;;+1;+2/p-3
IUPAC Name
magnesium(2+) ion (2-hydroxyethyl)trimethylazanium tris(2-hydroxybenzoate)
SMILES
[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O

Pharmacology

Indication

Choline magnesium trisalicylate is used to reduce pain and inflammation caused by conditions such as arthritis. This medication is also used to treat fever in adults.

Associated Conditions
Pharmacodynamics

Trisalicylate-choline is a non-steroidal anti-inflammatory drug (NSAID) that contains a combination of choline salicylate and magnesium salicylate. Does not affect platelet aggregation.

Mechanism of action

Inhibits prostaglandin synthesis; acts on the hypothalamus heat-regulating center to reduce fever; blocks the generation of pain impulses

TargetActionsOrganism
UProstaglandin G/H synthase 1
inhibitor
Human
UProstaglandin G/H synthase 2
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

renal

Half life
Not Available
Clearance
Not Available
Toxicity

Salicylate intoxication, known as salicylism, may occur with large doses or extended therapy. Common symptoms of salicylism include headache, dizziness, tinnitus, hearing impairment, confusion, drowsiness, sweating, vomiting, diarrhea, and hyperventilation. A more severe degree of salicylate intoxication can lead to CNS disturbances, alteration in electrolyte balance, respiratory and metabolic acidosis, hyperthermia, and dehydration.

Affected organisms
Not Available
Pathways
PathwayCategory
Trisalicylate-choline Action PathwayDrug action
Trisalicylate-choline Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Choline magnesium trisalicylate.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with 5-androstenedione.Experimental, Illicit
AbciximabCholine magnesium trisalicylate may increase the anticoagulant activities of Abciximab.Approved
AcebutololCholine magnesium trisalicylate may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolCholine magnesium trisalicylate may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Acetaminophen.Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Choline magnesium trisalicylate.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Choline magnesium trisalicylate.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Choline magnesium trisalicylate.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Alendronic acid.Approved
AliskirenCholine magnesium trisalicylate may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Choline magnesium trisalicylate.Experimental
AlprenololCholine magnesium trisalicylate may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Amcinonide.Approved
AmikacinCholine magnesium trisalicylate may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideCholine magnesium trisalicylate may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Aminosalicylic Acid.Approved
AmiodaroneCholine magnesium trisalicylate may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Choline magnesium trisalicylate.Approved
AncrodCholine magnesium trisalicylate may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Choline magnesium trisalicylate.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Choline magnesium trisalicylate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Antipyrine.Approved, Investigational
Antithrombin III humanCholine magnesium trisalicylate may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Antrafenine.Approved
ApixabanCholine magnesium trisalicylate may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Choline magnesium trisalicylate.Investigational
ApramycinCholine magnesium trisalicylate may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Choline magnesium trisalicylate.Approved, Investigational
ArbekacinCholine magnesium trisalicylate may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinCholine magnesium trisalicylate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanCholine magnesium trisalicylate may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololCholine magnesium trisalicylate may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineCholine magnesium trisalicylate may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Atamestane.Investigational
AtenololCholine magnesium trisalicylate may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Choline magnesium trisalicylate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Choline magnesium trisalicylate.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Choline magnesium trisalicylate.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Choline magnesium trisalicylate.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Choline magnesium trisalicylate.Approved, Investigational
BazedoxifeneCholine magnesium trisalicylate may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminCholine magnesium trisalicylate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololCholine magnesium trisalicylate may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinCholine magnesium trisalicylate may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Choline magnesium trisalicylate.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Choline magnesium trisalicylate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Choline magnesium trisalicylate.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Choline magnesium trisalicylate.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Choline magnesium trisalicylate.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Betamethasone.Approved, Vet Approved
BetaxololCholine magnesium trisalicylate may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Choline magnesium trisalicylate.Approved, Investigational
BevantololCholine magnesium trisalicylate may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Choline magnesium trisalicylate.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
BisoprololCholine magnesium trisalicylate may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinCholine magnesium trisalicylate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololCholine magnesium trisalicylate may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Choline magnesium trisalicylate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Choline magnesium trisalicylate.Investigational
BucindololCholine magnesium trisalicylate may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Bufexamac.Approved, Experimental
BufuralolCholine magnesium trisalicylate may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Choline magnesium trisalicylate.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
BupranololCholine magnesium trisalicylate may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Choline magnesium trisalicylate.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Choline magnesium trisalicylate.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Choline magnesium trisalicylate.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Choline magnesium trisalicylate.Approved, Vet Approved, Withdrawn
CarteololCholine magnesium trisalicylate may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCholine magnesium trisalicylate may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Choline magnesium trisalicylate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Choline magnesium trisalicylate.Approved, Investigational
CeliprololCholine magnesium trisalicylate may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinCholine magnesium trisalicylate may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Choline magnesium trisalicylate.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Vet Approved
ChlorotrianiseneCholine magnesium trisalicylate may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Choline magnesium trisalicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CiclesonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Cimicoxib.Investigational
CinoxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved
Citric AcidCholine magnesium trisalicylate may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Choline magnesium trisalicylate.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Choline magnesium trisalicylate.Vet Approved
CloranololCholine magnesium trisalicylate may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneCholine magnesium trisalicylate may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Choline magnesium trisalicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Choline magnesium trisalicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensCholine magnesium trisalicylate may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Choline magnesium trisalicylate.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Choline magnesium trisalicylate.Experimental
CyclosporineCholine magnesium trisalicylate may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateCholine magnesium trisalicylate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinCholine magnesium trisalicylate may increase the thrombogenic activities of Daidzein.Experimental
DalteparinCholine magnesium trisalicylate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidCholine magnesium trisalicylate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Choline magnesium trisalicylate.Investigational
DarexabanCholine magnesium trisalicylate may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Delapril.Investigational
DesipramineCholine magnesium trisalicylate may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinCholine magnesium trisalicylate may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Choline magnesium trisalicylate.Approved, Investigational
DextranCholine magnesium trisalicylate may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinCholine magnesium trisalicylate may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Choline magnesium trisalicylate.Approved, Vet Approved
DicoumarolCholine magnesium trisalicylate may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolCholine magnesium trisalicylate may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolCholine magnesium trisalicylate may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Choline magnesium trisalicylate.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Choline magnesium trisalicylate.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Choline magnesium trisalicylate.Approved
DihydrostreptomycinCholine magnesium trisalicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Choline magnesium trisalicylate.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Choline magnesium trisalicylate.Approved
DiphenadioneCholine magnesium trisalicylate may increase the anticoagulant activities of Diphenadione.Experimental
DrospirenoneCholine magnesium trisalicylate may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Choline magnesium trisalicylate.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Choline magnesium trisalicylate.Investigational
Edetic AcidCholine magnesium trisalicylate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanCholine magnesium trisalicylate may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Enalaprilat.Approved
EnoxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinCholine magnesium trisalicylate may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Choline magnesium trisalicylate.Experimental
EpanololCholine magnesium trisalicylate may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolCholine magnesium trisalicylate may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Choline magnesium trisalicylate.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Choline magnesium trisalicylate.Experimental
EplerenoneCholine magnesium trisalicylate may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Choline magnesium trisalicylate.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Choline magnesium trisalicylate.Approved
EquileninThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Equilin.Approved
EquolCholine magnesium trisalicylate may increase the thrombogenic activities of Equol.Investigational
EsatenololCholine magnesium trisalicylate may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved, Investigational
EsmololCholine magnesium trisalicylate may decrease the antihypertensive activities of Esmolol.Approved
EstradiolCholine magnesium trisalicylate may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateCholine magnesium trisalicylate may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateCholine magnesium trisalicylate may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateCholine magnesium trisalicylate may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolCholine magnesium trisalicylate may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedCholine magnesium trisalicylate may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Choline magnesium trisalicylate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Choline magnesium trisalicylate.Experimental
Ethinyl EstradiolCholine magnesium trisalicylate may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateCholine magnesium trisalicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Choline magnesium trisalicylate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Choline magnesium trisalicylate.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Choline magnesium trisalicylate.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Choline magnesium trisalicylate.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Choline magnesium trisalicylate.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Choline magnesium trisalicylate.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Choline magnesium trisalicylate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Choline magnesium trisalicylate.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Choline magnesium trisalicylate.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Choline magnesium trisalicylate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Choline magnesium trisalicylate.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Choline magnesium trisalicylate.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Choline magnesium trisalicylate.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fish oil.Approved, Nutraceutical
FleroxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Choline magnesium trisalicylate.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fludrocortisone.Approved, Investigational
FluindioneCholine magnesium trisalicylate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineCholine magnesium trisalicylate may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Choline magnesium trisalicylate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Choline magnesium trisalicylate.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluorometholone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Choline magnesium trisalicylate.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Choline magnesium trisalicylate.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluticasone propionate.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Nutraceutical, Vet Approved
FondaparinuxCholine magnesium trisalicylate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Choline magnesium trisalicylate.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fosinopril.Approved
FramycetinCholine magnesium trisalicylate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Vet Approved
GabexateCholine magnesium trisalicylate may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Withdrawn
GemifloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinCholine magnesium trisalicylate may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinCholine magnesium trisalicylate may increase the thrombogenic activities of Genistein.Investigational
GentamicinCholine magnesium trisalicylate may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ACholine magnesium trisalicylate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Choline magnesium trisalicylate.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with HE3286.Investigational
HeparinCholine magnesium trisalicylate may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolCholine magnesium trisalicylate may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Choline magnesium trisalicylate.Investigational
HydralazineCholine magnesium trisalicylate may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
Hygromycin BCholine magnesium trisalicylate may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Choline magnesium trisalicylate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Choline magnesium trisalicylate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Choline magnesium trisalicylate.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Icosapent.Approved, Nutraceutical
IdraparinuxCholine magnesium trisalicylate may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Choline magnesium trisalicylate.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Choline magnesium trisalicylate.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
IndenololCholine magnesium trisalicylate may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Choline magnesium trisalicylate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Choline magnesium trisalicylate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Choline magnesium trisalicylate.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Choline magnesium trisalicylate.Approved, Investigational
IsepamicinCholine magnesium trisalicylate may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Choline magnesium trisalicylate.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Istaroxime.Investigational
KanamycinCholine magnesium trisalicylate may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Choline magnesium trisalicylate.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Choline magnesium trisalicylate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Choline magnesium trisalicylate.Approved
LabetalolCholine magnesium trisalicylate may decrease the antihypertensive activities of Labetalol.Approved
LandiololCholine magnesium trisalicylate may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Choline magnesium trisalicylate.Approved, Investigational
LepirudinCholine magnesium trisalicylate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanCholine magnesium trisalicylate may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololCholine magnesium trisalicylate may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololCholine magnesium trisalicylate may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Choline magnesium trisalicylate.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Choline magnesium trisalicylate.Experimental
LomefloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Choline magnesium trisalicylate.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Choline magnesium trisalicylate.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Choline magnesium trisalicylate.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Choline magnesium trisalicylate.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Choline magnesium trisalicylate.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Choline magnesium trisalicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Choline magnesium trisalicylate.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Choline magnesium trisalicylate.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Choline magnesium trisalicylate.Approved
MelagatranCholine magnesium trisalicylate may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Choline magnesium trisalicylate.Approved, Vet Approved
MepindololCholine magnesium trisalicylate may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Choline magnesium trisalicylate.Approved
MestranolCholine magnesium trisalicylate may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Choline magnesium trisalicylate.Approved, Investigational, Withdrawn
MethallenestrilCholine magnesium trisalicylate may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Choline magnesium trisalicylate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Methylprednisolone.Approved, Vet Approved
MetipranololCholine magnesium trisalicylate may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Choline magnesium trisalicylate.Approved
MetoprololCholine magnesium trisalicylate may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinCholine magnesium trisalicylate may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Choline magnesium trisalicylate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Choline magnesium trisalicylate.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Choline magnesium trisalicylate.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Choline magnesium trisalicylate.Approved
MoxestrolCholine magnesium trisalicylate may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Choline magnesium trisalicylate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Choline magnesium trisalicylate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Choline magnesium trisalicylate.Approved
NadololCholine magnesium trisalicylate may decrease the antihypertensive activities of Nadolol.Approved
NadroparinCholine magnesium trisalicylate may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Choline magnesium trisalicylate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Choline magnesium trisalicylate.Approved
Nalidixic AcidCholine magnesium trisalicylate may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Choline magnesium trisalicylate.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with NCX 1022.Investigational
NeamineCholine magnesium trisalicylate may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololCholine magnesium trisalicylate may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved, Withdrawn
NemonoxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinCholine magnesium trisalicylate may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Choline magnesium trisalicylate.Approved, Investigational
NetilmicinCholine magnesium trisalicylate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Choline magnesium trisalicylate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Choline magnesium trisalicylate.Investigational
NorfloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Choline magnesium trisalicylate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Choline magnesium trisalicylate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Choline magnesium trisalicylate.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Choline magnesium trisalicylate is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Choline magnesium trisalicylate.Vet Approved
OtamixabanCholine magnesium trisalicylate may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Choline magnesium trisalicylate.Approved
Oxolinic acidCholine magnesium trisalicylate may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololCholine magnesium trisalicylate may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Choline magnesium trisalicylate.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Choline magnesium trisalicylate.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Parecoxib.Approved
ParomomycinCholine magnesium trisalicylate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Choline magnesium trisalicylate.Approved, Investigational
PazufloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololCholine magnesium trisalicylate may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateCholine magnesium trisalicylate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateCholine magnesium trisalicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Perindopril.Approved
PhenindioneCholine magnesium trisalicylate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonCholine magnesium trisalicylate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Choline magnesium trisalicylate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Choline magnesium trisalicylate.Approved, Investigational
PindololCholine magnesium trisalicylate may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidCholine magnesium trisalicylate may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Choline magnesium trisalicylate.Approved, Investigational
Piromidic acidCholine magnesium trisalicylate may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Choline magnesium trisalicylate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Choline magnesium trisalicylate.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorCholine magnesium trisalicylate may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinCholine magnesium trisalicylate may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphateCholine magnesium trisalicylate may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pomalidomide.Approved
Potassium CitrateCholine magnesium trisalicylate may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololCholine magnesium trisalicylate may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Choline magnesium trisalicylate.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Choline magnesium trisalicylate.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Choline magnesium trisalicylate can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Choline magnesium trisalicylate.Experimental
PromestrieneCholine magnesium trisalicylate may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Choline magnesium trisalicylate.Approved, Investigational
PropafenoneCholine magnesium trisalicylate may decrease the antihypertensive activities of Propafenone.Approved
PropranololCholine magnesium trisalicylate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Choline magnesium trisalicylate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Choline magnesium trisalicylate.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Choline magnesium trisalicylate.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Choline magnesium trisalicylate.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Choline magnesium trisalicylate.Vet Approved
Protein CCholine magnesium trisalicylate may increase the anticoagulant activities of Protein C.Approved
Protein S humanCholine magnesium trisalicylate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeCholine magnesium trisalicylate may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Choline magnesium trisalicylate.Investigational
PuromycinCholine magnesium trisalicylate may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Quinapril.Approved, Investigational
QuinestrolCholine magnesium trisalicylate may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Choline magnesium trisalicylate.Approved
RamiprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinCholine magnesium trisalicylate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinCholine magnesium trisalicylate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Risedronate.Approved, Investigational
RivaroxabanCholine magnesium trisalicylate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Choline magnesium trisalicylate.Approved, Investigational, Withdrawn
RosoxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Choline magnesium trisalicylate.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Choline magnesium trisalicylate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Choline magnesium trisalicylate.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Choline magnesium trisalicylate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Choline magnesium trisalicylate.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Choline magnesium trisalicylate.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Choline magnesium trisalicylate.Approved, Investigational
SecoisolariciresinolCholine magnesium trisalicylate may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Choline magnesium trisalicylate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Choline magnesium trisalicylate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Choline magnesium trisalicylate.Investigational
SertralineSertraline may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved
SisomicinCholine magnesium trisalicylate may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateCholine magnesium trisalicylate may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicSodium phosphate may increase the nephrotoxic activities of Choline magnesium trisalicylate.Approved
SotalolCholine magnesium trisalicylate may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Spirapril.Approved
SpironolactoneCholine magnesium trisalicylate may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Choline magnesium trisalicylate.Investigational
StreptomycinCholine magnesium trisalicylate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Choline magnesium trisalicylate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Choline magnesium trisalicylate.Approved, Investigational
SulodexideCholine magnesium trisalicylate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Choline magnesium trisalicylate.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Choline magnesium trisalicylate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Choline magnesium trisalicylate.Experimental
Synthetic Conjugated Estrogens, ACholine magnesium trisalicylate may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BCholine magnesium trisalicylate may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusCholine magnesium trisalicylate may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved
TalinololCholine magnesium trisalicylate may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Choline magnesium trisalicylate.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Choline magnesium trisalicylate.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Choline magnesium trisalicylate.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Choline magnesium trisalicylate.Approved, Investigational
TemafloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Choline magnesium trisalicylate.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Choline magnesium trisalicylate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Choline magnesium trisalicylate.Vet Approved
TerbutalineCholine magnesium trisalicylate may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Choline magnesium trisalicylate.Approved
TertatololCholine magnesium trisalicylate may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tiaprofenic acid.Approved
TiboloneCholine magnesium trisalicylate may increase the thrombogenic activities of Tibolone.Approved, Investigational
Tiludronic acidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololCholine magnesium trisalicylate may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Choline magnesium trisalicylate.Investigational
TioclomarolCholine magnesium trisalicylate may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tixocortol.Approved, Withdrawn
TobramycinCholine magnesium trisalicylate may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Choline magnesium trisalicylate.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Choline magnesium trisalicylate.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Choline magnesium trisalicylate.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Choline magnesium trisalicylate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Triamcinolone.Approved, Vet Approved
TriamtereneCholine magnesium trisalicylate may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Choline magnesium trisalicylate.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Choline magnesium trisalicylate.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Trolamine salicylate.Approved
TrovafloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinCholine magnesium trisalicylate may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Choline magnesium trisalicylate.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Choline magnesium trisalicylate.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Choline magnesium trisalicylate.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved
WarfarinCholine magnesium trisalicylate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranCholine magnesium trisalicylate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Choline magnesium trisalicylate.Approved, Investigational
ZeranolCholine magnesium trisalicylate may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Choline magnesium trisalicylate.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Choline magnesium trisalicylate.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Choline magnesium trisalicylate.Withdrawn
Food Interactions
Not Available

References

General References
  1. Nadkarni MM, Peller CA, Retig J: Eosinophilic hepatitis after ingestion of choline magnesium trisalicylate. Am J Gastroenterol. 1992 Jan;87(1):151-3. [PubMed:1728115]
  2. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC: The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1992;42(2):121-5. [PubMed:1618240]
External Links
Human Metabolome Database
HMDB0015473
PubChem Compound
54682045
PubChem Substance
46505243
ChemSpider
10642393
PharmGKB
PA164749164

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Ivax Pharmaceuticals
  • Pliva Inc.
Dosage forms
FormRouteStrength
LiquidOral500 mg/5mL
Prices
Unit descriptionCostUnit
Choline mag trisal 1 gm tablet1.23USD tablet
Choline mag trisal 750 mg tablet0.81USD tablet
Choline mag trisal 500 mg tablet0.57USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP1.98ChemAxon
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity46.13 m3·mol-1ChemAxon
Polarizability12.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9852
Blood Brain Barrier-0.8993
Caco-2 permeable+0.5436
P-glycoprotein substrateSubstrate0.7681
P-glycoprotein inhibitor INon-inhibitor0.9522
P-glycoprotein inhibitor IINon-inhibitor0.6479
Renal organic cation transporterNon-inhibitor0.7147
CYP450 2C9 substrateNon-substrate0.7398
CYP450 2D6 substrateNon-substrate0.7764
CYP450 3A4 substrateSubstrate0.588
CYP450 1A2 substrateNon-inhibitor0.7658
CYP450 2C9 inhibitorNon-inhibitor0.8703
CYP450 2D6 inhibitorNon-inhibitor0.7642
CYP450 2C19 inhibitorNon-inhibitor0.8941
CYP450 3A4 inhibitorNon-inhibitor0.9072
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9752
Ames testNon AMES toxic0.7389
CarcinogenicityNon-carcinogens0.729
BiodegradationReady biodegradable0.5807
Rat acute toxicity2.3576 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8568
hERG inhibition (predictor II)Non-inhibitor0.7428
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylic acids
Alternative Parents
Benzoic acids / Benzoyl derivatives / Phenoxides / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Cholines / Vinylogous acids / Tetraalkylammonium salts / 1,2-aminoalcohols / Carboxylic acid salts
show 7 more
Substituents
Salicylic acid / Benzoic acid / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Choline / Phenol / Phenoxide / Tetraalkylammonium salt / Vinylogous acid
show 19 more
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Nizankowska E, Dworski R, Soja J, Szczeklik A: Salicylate pre-treatment attenuates intensity of bronchial and nasal symptoms precipitated by aspirin in aspirin-intolerant patients. Clin Exp Allergy. 1990 Nov;20(6):647-52. [PubMed:2083404]
  2. Simon RA: Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. [PubMed:14680616]
  3. Schwartz KA: Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility. Adv Clin Chem. 2006;42:81-110. [PubMed:17131625]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Simon RA: Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. [PubMed:14680616]
  2. Brzozowski T, Konturek PC, Sliwowski Z, Kwiecien S, Drozdowicz D, Pawlik M, Mach K, Konturek SJ, Pawlik WW: Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol. 2006 Sep;57 Suppl 3:67-79. [PubMed:17033106]
  3. Wang HJ, Liu XJ, Yang KX, Luo FM, Lou JY, Peng ZL: [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Sep;37(5):757-60. [PubMed:17037745]
  4. Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006;8(6):R71. [PubMed:17181859]
  5. Nakano M, Denda N, Matsumoto M, Kawamura M, Kawakubo Y, Hatanaka K, Hiramoto Y, Sato Y, Noshiro M, Harada Y: Interaction between cyclooxygenase (COX)-1- and COX-2-products modulates COX-2 expression in the late phase of acute inflammation. Eur J Pharmacol. 2007 Mar 22;559(2-3):210-8. Epub 2006 Dec 16. [PubMed:17258197]

Drug created on July 08, 2007 11:07 / Updated on August 02, 2018 04:35